Literature DB >> 22406096

The possible underlying pathophysiological mechanisms for development of multiple sclerosis in familial Mediterranean fever.

Mahmut Alpayci1, Nazim Bozan, Seyfettin Erdem, Muslum Gunes, Metin Erden.   

Abstract

Patients with familial Mediterranean fever (FMF) have a susceptibility to the development of multiple sclerosis (MS). Here, we will propose the possible underlying pathophysiological mechanisms of this predisposition. Inflammation, disruption of blood-brain barrier (BBB), mitochondrial energy deficit, demyelination, and axonal damage, which play an important role in the pathogenesis of MS, may occur during the course of FMF. Most FMF patients have homozygous mutations in the MEFV gene that codes for the protein pyrin. Also, pyrin mutations were found about 3.5 times higher in the MS patients than the healthy control group. Pyrin is implicated in the maturation and secretion of the proinflammatory cytokine IL-1β. IL-1β is a major mediator of fever and systemic inflammation, and mononuclear cells from FMF patients release higher levels of IL-1β. Moreover, IL-1 plays a significant role in the regulation of the T-cells, and it is considered an essential cytokine for the Th cell differentiation that implicated in the MS pathogenesis. In addition, endothelial dysfunction and vasculitis in FMF may cause BBB breakdown that is the first step in the development of MS lesions. Apart from this, damage can occur in myelin and mitochondria proteins due to high body temperature that arises during the FMF attacks. Whereas the protein damage in myelin results in demyelination, and the protein damage in mitochondria causes lack of energy. Both situations play a part in the pathogenesis of MS. Due to mitochondrial energy deficit, remyelination may not be achieved, and therefore, axonal damage increases. Thus, at the end of these pathophysiological processes, MS findings may occur in the FMF patients especially with irregular use of colchicine.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22406096     DOI: 10.1016/j.mehy.2012.02.017

Source DB:  PubMed          Journal:  Med Hypotheses        ISSN: 0306-9877            Impact factor:   1.538


  8 in total

Review 1.  Differential diagnosis of Mendelian and mitochondrial disorders in patients with suspected multiple sclerosis.

Authors:  James D Weisfeld-Adams; Ilana B Katz Sand; Justin M Honce; Fred D Lublin
Journal:  Brain       Date:  2015-01-29       Impact factor: 13.501

2.  Familiar Mediterranean fever and multiple sclerosis: an unreported association in the Italian population?

Authors:  Margherita Russo; Antonino Naro; Vincenzo Dattola; Romina Gallizzi; Rocco Salvatore Calabrò; Maria Buccafusca
Journal:  Neurol Sci       Date:  2014-08-13       Impact factor: 3.307

3.  Association of missense mutations of Mediterranean fever (MEFV) gene with multiple sclerosis in Turkish population.

Authors:  Serbulent Yigit; Nevin Karakus; Semiha Gülsüm Kurt; Omer Ates
Journal:  J Mol Neurosci       Date:  2013-01-08       Impact factor: 3.444

Review 4.  Immunology and oxidative stress in multiple sclerosis: clinical and basic approach.

Authors:  Genaro G Ortiz; Fermín P Pacheco-Moisés; Oscar K Bitzer-Quintero; Ana C Ramírez-Anguiano; Luis J Flores-Alvarado; Viridiana Ramírez-Ramírez; Miguel A Macias-Islas; Erandis D Torres-Sánchez
Journal:  Clin Dev Immunol       Date:  2013-09-24

5.  Anti-CCP antibody levels are not associated with MS: results from a case-control study.

Authors:  Mahmut Alpayci; Aysel Milanlioglu; Veysel Delen; Mehmet Nuri Aydin; Huseyin Guducuoglu; Yasemin Bayram
Journal:  Biomed Res Int       Date:  2015-02-02       Impact factor: 3.411

6.  Multi-Target Protective Effects of Gintonin in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Mediated Model of Parkinson's Disease via Lysophosphatidic Acid Receptors.

Authors:  Jong Hee Choi; Minhee Jang; Seikwan Oh; Seung-Yeol Nah; Ik-Hyun Cho
Journal:  Front Pharmacol       Date:  2018-05-23       Impact factor: 5.810

7.  Case Report: Efficacy of Rituximab in a Patient With Familial Mediterranean Fever and Multiple Sclerosis.

Authors:  Mattia Pozzato; Emanuele Micaglio; Chiara Starvaggi Cucuzza; Alessandro Cagol; Daniela Galimberti; Daniela Calandrella; Claudia Cinnante; Carlo Pappone; Monica Zanussi; Giovanni Meola; Elio Scarpini; Nereo Bresolin; Filippo Martinelli Boneschi
Journal:  Front Neurol       Date:  2021-01-06       Impact factor: 4.003

8.  Positive effects of ocrelizumab in patients with familial mediterranean fever and coexistent multiple sclerosis.

Authors:  Caner Feyzi Demir; Ferhat BALGETiR; Özlem Ethemoğlu; Dürdane Aksoy; Filiz Aktaş; Süleyman Serdar Koca; Mehmet Fatih Yetkin; İrem Taşci
Journal:  Arch Rheumatol       Date:  2021-01-14       Impact factor: 1.472

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.